skip to the content

TAnDEM trial

 

A Phase III, randomised, controlled, open-label study comparing Herceptin plus an aromatase inhibitor (anastrozole) with anastrozole alone as first-line treatment in post-menopausal patients with HER2/hormone receptor co-positive MBC.